Annovis Bio Stock Alpha and Beta Analysis

ANVS Stock  USD 6.65  0.14  2.06%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Annovis Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Annovis Bio over a specified time horizon. Remember, high Annovis Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Annovis Bio's market risk premium analysis include:
Beta
0.83
Alpha
(0.51)
Risk
4.15
Sharpe Ratio
(0.12)
Expected Return
(0.49)
Please note that although Annovis Bio alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Annovis Bio did 0.51  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Annovis Bio stock's relative risk over its benchmark. Annovis Bio has a beta of 0.83  . As returns on the market increase, Annovis Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Annovis Bio is expected to be smaller as well. Book Value Per Share is likely to gain to -0.82 in 2024. Tangible Book Value Per Share is likely to gain to -0.82 in 2024.

Enterprise Value

44.9 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Annovis Bio Backtesting, Annovis Bio Valuation, Annovis Bio Correlation, Annovis Bio Hype Analysis, Annovis Bio Volatility, Annovis Bio History and analyze Annovis Bio Performance.
For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.

Annovis Bio Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Annovis Bio market risk premium is the additional return an investor will receive from holding Annovis Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Annovis Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Annovis Bio's performance over market.
α-0.51   β0.83

Annovis Bio expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Annovis Bio's Buy-and-hold return. Our buy-and-hold chart shows how Annovis Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Annovis Bio Market Price Analysis

Market price analysis indicators help investors to evaluate how Annovis Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Annovis Bio shares will generate the highest return on investment. By understating and applying Annovis Bio stock market price indicators, traders can identify Annovis Bio position entry and exit signals to maximize returns.

Annovis Bio Return and Market Media

The median price of Annovis Bio for the period between Sun, Aug 25, 2024 and Sat, Nov 23, 2024 is 8.36 with a coefficient of variation of 9.87. The daily time series for the period is distributed with a sample standard deviation of 0.82, arithmetic mean of 8.36, and mean deviation of 0.63. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
BioMedNewsBreaks Annovis Bio Inc. to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
09/05/2024
2
BioMedNewsBreaks Annovis Bio Inc. Stands Distinct from Industry Players with Buntanetap
09/20/2024
3
BioMedNewsBreaks Annovis Bio Inc. Announces Filing of Three Patents Covering Combination Therapies for AD, PD
09/30/2024
4
Annovis Bio Inc. Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
10/03/2024
5
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimers Studies, Paving the Way to NDAs
10/15/2024
6
Annovis Bio Shows Promise on FDA Clearance for Alzheimers Drug
10/17/2024
7
Acquisition by Maria Maccecchini of 21312 shares of Annovis Bio subject to Rule 16b-3
10/18/2024
8
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
11/07/2024
9
Annovis Bio Posts Quarterly Earnings Results, Misses Expectations By 0.33 EPS
11/12/2024
10
Q4 Earnings Estimate for Annovis Bio Issued By HC Wainwright
11/14/2024

About Annovis Bio Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Annovis or other stocks. Alpha measures the amount that position in Annovis Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Annovis Bio Upcoming Company Events

As portrayed in its financial statements, the presentation of Annovis Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Annovis Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Annovis Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Annovis Bio. Please utilize our Beneish M Score to check the likelihood of Annovis Bio's management manipulating its earnings.
1st of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Annovis Bio

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Annovis Stock Analysis

When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.